A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection

Sponsor

Huahui Health (Industry)

Overall Status

Not yet recruiting

CT.gov ID

NCT05861674

Collaborator

(none)

Enrollment

Arms

25.5

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

This is a multicenter, randomized, controlled, open-label, Phase IIb study of HH-003 injection, HH-003 injection is a monoclonal antibody targeting Hepatitis B virus. This study aims to assess efficacy and safety in subjects with chronic hepatitis delta virus infection.

Condition or Disease	Intervention/Treatment	Phase
Chronic Hepatitis Delta Virus Infection	Biological: HH-003(20mg/kg) Biological: HH-003(10mg/kg) Drug: TAF	Phase 2

Study Design

Study Type:

Interventional

Anticipated Enrollment :

80 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Masking:

None (Open Label)

Primary Purpose:

Treatment

Official Title:

A Multicenter, Randomized, Controlled, Open-label Phase IIb Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection

Anticipated Study Start Date :

May 17, 2023

Anticipated Primary Completion Date :

Jun 30, 2024

Anticipated Study Completion Date :

Jun 30, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: HH-003 (20mg/kg)+TAF Subjects will receive HH-003 20 mg/kg Q2W intravenously and TAF 25 mg QD orally during 48-week treatment period, and receive TAF 25 mg QD orally during 24-week follow-up period.	Biological: HH-003(20mg/kg) 20 mg/kg Q2W intravenously for 48 weeks Drug: TAF TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period
Experimental: HH-003 (10mg/kg)+TAF Subjects will receive HH-003 10 mg/kg Q2W intravenously and TAF 25 mg QD orally during 48-week treatment period, and receive TAF 25 mg QD orally during 24-week follow-up period.	Biological: HH-003(10mg/kg) 10 mg/kg Q2W intravenously for 48 weeks Drug: TAF TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period
Other: TAF Subjects will receive TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period.	Drug: TAF TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period

Arm

Intervention/Treatment

Experimental: HH-003 (20mg/kg)+TAF

Subjects will receive HH-003 20 mg/kg Q2W intravenously and TAF 25 mg QD orally during 48-week treatment period, and receive TAF 25 mg QD orally during 24-week follow-up period.

Biological: HH-003(20mg/kg)

20 mg/kg Q2W intravenously for 48 weeks

Drug: TAF

TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period

Experimental: HH-003 (10mg/kg)+TAF

Subjects will receive HH-003 10 mg/kg Q2W intravenously and TAF 25 mg QD orally during 48-week treatment period, and receive TAF 25 mg QD orally during 24-week follow-up period.

Biological: HH-003(10mg/kg)

10 mg/kg Q2W intravenously for 48 weeks

Drug: TAF

TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period

Other: TAF

Subjects will receive TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period.

Drug: TAF

TAF 25 mg QD orally during 48-week treatment period and 24-week follow-up period

Outcome Measures

Primary Outcome Measures

Proportion of subjects with serum HDV RNA below the lower limit of detection or a decrease of ≥2 log10 IU/mL from baseline and ALT normalization [At Week 24 of the treatment period]

Secondary Outcome Measures

Proportion of subjects with serum HDV RNA below the lower limit of detection or a decrease of ≥2 log10 IU/mL from baseline [At Week 24 of the treatment period]
Proportion of subjects with ALT normalization [At Week 24 of the treatment period]
Change from baseline in liver stiffness measurement (LSM) [At Week 24 of the treatment period]
Proportion of subjects with serum HDV RNA below the lower limit of detection or a decrease of ≥2 log10 IU/mL from baseline and ALT normalization [At Week 48 of the treatment period]
Proportion of subjects with serum HDV RNA below the lower limit of detection or a decrease of ≥2 log10 IU/mL from baseline [At Week 48 of the treatment period]
Proportion of subjects with ALT normalization [At Week 48 of the treatment period]
Change from baseline in liver stiffness measurement (LSM) [At Week 48 of the treatment period]
Proportion of subjects with serum HDV RNA below the lower limit of detection or a decrease of ≥2 log10 IU/mL from baseline [At Week 24 of the follow-up period]
Proportion of subjects with ALT normalization [At Week 24 of the follow-up period]
Change from baseline in liver stiffness measurement (LSM) [At Week 24 of the follow-up period]
Change from baseline in serum HDV RNA levels at different time points [Up to Week 72]
Change from baseline in serum ALT levels at different time points [Up to Week 72]

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 70 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Signed the informed consent form;
Male or female aged 18 to 70 years;
Positive HBsAg at screening;
History of chronic HDV infection for at least 6 months prior to randomization. For subjects also recommended for anti-HBV therapy, previous first line NrtIs treatment (ETV, TDF, TAF) within at least 12 weeks prior to the planned start of study treatment or subject's willingness to take first line NrtIs treatment for at least 12 weeks prior to the planned start of study treatment is required;
Positive HDV antibody at screening;
HDV RNA ≥100 IU/mL at screening;
1×ULN<Alanine aminotransferase (ALT) <10×ULN at screening;

Exclusion Criteria:

Subjects with known hypersensitivity to HH-003 and its components, history of severe allergic reaction to other therapeutic antibodies or severe allergic diseases;
Subjects with contraindications for TAF;
History of interferon therapy within 3 months before randomization;
Any of the following lab test results at screening:

Total bilirubin >2×ULN (except for subjects with Gilbert syndrome);
Direct bilirubin > 1.5×ULN ;
Platelets<80,000/mm3 (80×109/L);
Serum Albumin <35 g/L;
Prothrombin time international normalized ratio (INR) >1.3;
Hemoglobin <100 g/L;
Absolute neutrophils<1,500/mm3 (1.5×109/L);
Estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73m2 (according to the calculation equation of CKD-MDRD);

Concomitant decompensated cirrhosis (cirrhosis with complications of portal hypertension and/or decreased hepatic function). The diagnosis of cirrhosis is based on, but not limited to: liver imaging assessment within 6 months prior to randomization (including screening period) (e.g.: liver ultrasound) or cirrhosis indicated by histopathology of liver biopsy, or liver stiffness measurement LSM≥17 kPa at screening, refer to more serious reported findings;
Hepatic insufficiency within 3 months prior to randomization (including but not limited to: ascites, hepatic encephalopathy, upper gastrointestinal hemorrhage);
Previous or current hepatocellular carcinoma (HCC) or suspicion for HCC suggested by liver histopathology or liver imaging; or serum alpha-fetoprotein (AFP) ≥ 50 ng/mL at screening;
Subjects with history of alcoholic liver disease, nonalcoholic steatohepatitis, autoimmune liver disease or other hereditary liver diseases, drug-induced liver disease or other clinically significant chronic liver diseases not caused by HDV/HBV;
History of other malignancies other than HCC, unless the subject's malignancy has been in complete remission within 3 years prior to screening and does not require chemotherapy and additional medical or surgical intervention; invasive medical devices within 1 month before randomization.